SCHEMBL14235747

SCHEMBL14235747

CCc1ccc(C(=O)c2cc(Br)c3c(c2Br)CCC3)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.45
▸ SMN1; SMN2 Q16637 4/20 0.45
▸ HTT P42858 3/20 0.45
▸ PLK1 P53350 1/20 0.40
▸ ALDH1A1 P00352 6/20 0.39
▸ SLC5A1 P13866 2/20 0.39
▸ SLC5A2 P31639 2/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ RAB9A P51151 4/20 0.38
▸ NPC1 O15118 3/20 0.38
▸ HPGD P15428 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ TP53 P04637 1/20 0.37
▸ CNR1 P21554 1/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ GNG2 P59768 1/20 0.36
▸ GNB1 P62873 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14236166 0.83 KDM4E (0.47) MAPTSMN1; SMN2PLK1ALDH1A1SLC5A1
SCHEMBL15610796 0.81 MAPT (0.49) MAPTHTTALDH1A1SLC5A1SLC5A2
SCHEMBL14236003 0.76 SLC5A2 (0.53) SLC5A1SLC5A2
SCHEMBL24199843 0.74 MAPT (0.51) MAPTSMN1; SMN2HTTPLK1ALDH1A1
SCHEMBL21362751 0.73 ALDH1A1 (0.60) MAPTSMN1; SMN2HTTPLK1ALDH1A1
SCHEMBL1253396 0.72 MAPT (0.47) MAPTSMN1; SMN2HTTPLK1ALDH1A1
SCHEMBL14236172 0.71 SMN1; SMN2 (0.40) MAPTSMN1; SMN2HTTALDH1A1MEN1
SCHEMBL29723114 0.71 SMN1; SMN2 (0.40) SMN1; SMN2HTTALDH1A1MEN1KMT2A
SCHEMBL14128389 0.71 SMN1; SMN2 (0.40) SMN1; SMN2HTTALDH1A1MEN1KMT2A
SCHEMBL1252927 0.70 MAPT (0.48) MAPTSMN1; SMN2HTTPLK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2714032-B1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORP (KR) 2019-01-16 — — EP disclosed
EP-2714032-B1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORP (KR) 2019-01-16 — — EP disclosed
US-9371303-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2016-06-21 — — US disclosed
US-9371303-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2016-06-21 — — US disclosed
US-9371303-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2016-06-21 — — US disclosed
US-20150152075-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2015-06-04 — — US disclosed
US-20150152075-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2015-06-04 — — US disclosed
US-9034921-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2015-05-19 — — US disclosed
US-9034921-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2015-05-19 — — US disclosed
US-9034921-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2015-05-19 — — US disclosed
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-03-27 — — US disclosed
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-03-27 — — US disclosed
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-03-27 — — US disclosed
WO-2012165914-A2 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2012-12-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS SLC5A2, SLC5A1, SLC2A8 MAPT 1050/4885SMN1; SMN2 4345/4885HTT 3131/4885
US-20150152075-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS SLC5A2, SLC5A1, SLC2A8 MAPT 910/4885SMN1; SMN2 4006/4885HTT 3173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback